# TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

> **NCT04485013** · PHASE1 · RECRUITING · sponsor: **Tizona Therapeutics, Inc** · enrollment: 240 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** TTX-080
- **DRUG:** TTX-080
- **DRUG:** pembrolizumab
- **DRUG:** cetuximab
- **DRUG:** FOLFIRI
- **DRUG:** cetuximab
- **DRUG:** TTX-080

## Key facts

- **NCT ID:** NCT04485013
- **Lead sponsor:** Tizona Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-14
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04485013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04485013, "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04485013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*